The federal TrumpRx marketplace rollout was delayed amid increased congressional scrutiny and questions about anti‑kickback compliance, the Office of Inspector General and HHS oversight. Senators including Dick Durbin and Elizabeth Warren have sought answers on how the platform will route patients, protect against inappropriate prescribing and avoid conflicts of interest. HHS issued advisory guidance on safeguards for pharma participation, including restrictions on billing federal programs, independent prescriber verification, and limits on controlled substances. Several major pharma companies had signed up to offer discounted drugs, but the delay leaves the program’s legal and operational model unsettled. The pause raises regulatory and compliance risks for direct‑to‑consumer pharma marketplaces and signals that lawmakers will closely examine novel procurement and distribution models that intersect with telehealth and pharmaceutical marketing.